Abstract
The pharmaceutical industry is interested in developing new treatments for severe asthma (SA), recognising that there is a substantial unmet clinical need in this area. However, it faces a significant set of barriers in attempting to do so, including a) problems arising from the way SA is defined, b) the heterogeneity of this condition, c) poor understanding of its aetiology, d) the absence of validated animal and tissue or cellular models, e) the need for biomarkers and experimental clinical models of severe asthma and its sub-groups, and f) the length and size of the clinical trials likely to be required to obtain approval and reimbursement. The discovery and validation of novel biomarkers and surrogates is likely to be a crucial part of meeting these challenges, and many academic groups and pharmaceutical companies working in this area are increasingly turning to pre-competitive, highly collaborative ways of working to address them.
Keywords: Refractory asthma, difficult asthma, segmentation, phenotypes, biomarkers, collaboration, symptomatic, moderate asthma, budesonide, therapeutics, Severe asthma, hypothesised, aetiology, sputum eosinophil, epigenetic, biological flui, prednisolone, Diseases Symposium, Cohort Studies
Current Pharmaceutical Design
Title: Challenges for the Development of New Treatments for Severe Asthma: A Pharmaceutical Perspective
Volume: 17 Issue: 7
Author(s): Richard G. Knowles
Affiliation:
Keywords: Refractory asthma, difficult asthma, segmentation, phenotypes, biomarkers, collaboration, symptomatic, moderate asthma, budesonide, therapeutics, Severe asthma, hypothesised, aetiology, sputum eosinophil, epigenetic, biological flui, prednisolone, Diseases Symposium, Cohort Studies
Abstract: The pharmaceutical industry is interested in developing new treatments for severe asthma (SA), recognising that there is a substantial unmet clinical need in this area. However, it faces a significant set of barriers in attempting to do so, including a) problems arising from the way SA is defined, b) the heterogeneity of this condition, c) poor understanding of its aetiology, d) the absence of validated animal and tissue or cellular models, e) the need for biomarkers and experimental clinical models of severe asthma and its sub-groups, and f) the length and size of the clinical trials likely to be required to obtain approval and reimbursement. The discovery and validation of novel biomarkers and surrogates is likely to be a crucial part of meeting these challenges, and many academic groups and pharmaceutical companies working in this area are increasingly turning to pre-competitive, highly collaborative ways of working to address them.
Export Options
About this article
Cite this article as:
G. Knowles Richard, Challenges for the Development of New Treatments for Severe Asthma: A Pharmaceutical Perspective, Current Pharmaceutical Design 2011; 17 (7) . https://dx.doi.org/10.2174/138161211795429019
DOI https://dx.doi.org/10.2174/138161211795429019 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transient Receptor Potential Vanilloid 1 and Xenobiotics
CNS & Neurological Disorders - Drug Targets Targeting MAPK Signalling: Prometheus Fire or Pandoras Box?
Current Pharmaceutical Design Modulation of Neutrophil Function by Hormones
Current Immunology Reviews (Discontinued) Targeted Delivery of Montelukast for the Treatment of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Adipose Tissue in the Regulation of Inflammation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) A3 Adenosine Receptor Antagonists
Mini-Reviews in Medicinal Chemistry Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Patterns of Self-Medication with Medicinal Plants and Related Adverse Events - A South American Survey
Current Drug Safety New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry Experimental Bronchial Asthma – The Strength of the Species Rat
Current Drug Targets Potentially Inappropriate Medication Use in Older People: A Crosssectional Study Using Beers Criteria
Current Drug Safety Room Temperature Metal-Free Synthesis of Aryl/Heteroaryl-Substituted Bis(6-aminouracil-5-yl)methanes Using Sulfamic Acid (NH2SO3H) as an Efficient and Eco-friendly Organo-Catalyst
Current Organocatalysis Prediction and Prevention of Abnormal Antenatal Lung Growth
Current Respiratory Medicine Reviews Efficacy and Safety of Corticosteroids’ Administration for Pulmonary Immaturity in Anticipated Preterm Delivery
Current Pharmaceutical Design Optimized and Comparative Antioxidant Assays and Its Applications in Herbal and Synthetic Drug Analysis as an Antioxidants
Mini-Reviews in Medicinal Chemistry Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry Editorial from Editor-in-Chief: Alternative and Complementary Medicine in Pulmonary Conditions
Current Respiratory Medicine Reviews Herbal Immunomodulators - A Remedial Panacea for Designing and Developing Effective Drugs and Medicines: Current Scenario and Future Prospects
Current Drug Metabolism Small Molecule Inhibitors of Phosphoinositide 3-Kinase (PI3K) δ and γ
Current Topics in Medicinal Chemistry Defensive and Offensive Cross-Reactive Antibodies Elicited by Pathogens: The Good, the Bad and the Ugly
Current Medicinal Chemistry